Orlifit-N-Slim 120 Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. It acts by selectively inhibiting gastric and pancreatic lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Orlistat facilitates weight reduction in conjunction with a reduced-calorie diet. This medication is prescribed for adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who have associated risk factors such as hypertension, diabetes mellitus, or dyslipidemia. Orlifit-N-Slim 120 Capsule is to be taken orally with each main meal containing fat, typically three times daily. Patients are advised to adhere to a nutritionally balanced, hypocaloric diet to optimize therapeutic outcomes and minimize gastrointestinal side effects such as steatorrhea, oily spotting, and flatulence. The safety profile necessitates monitoring for fat-soluble vitamin deficiencies; supplementation may be required. Orlistat is contraindicated in chronic malabsorption syndromes and cholestasis. Regular follow-up is recommended to assess efficacy, tolerability, and adherence to lifestyle modifications.